Skip to main content
. 2022 Oct 10;28(10):2083–2091. doi: 10.1038/s41591-022-02026-4

Extended Data Fig. 7. Prevalence and duration of gastrointestinal events by severity.

Extended Data Fig. 7

(a-d) The proportion of participants receiving semaglutide or placebo who reported nausea (a), diarrhea (b), constipation (c), or vomiting (d) events classed as mild, moderate, or severe over the course of the treatment period. Data are from the on-treatment observation period (during treatment with trial product [any dose of trial medication administered within the previous 49 days (that is, any period of temporary treatment interruption with trial product was excluded)). Adverse events were classified by severity as mild (easily tolerated, causing minimal discomfort, and not interfering with everyday activities), moderate (causes sufficient discomfort and interferes with normal everyday activities), or severe (prevents normal everyday activities).